Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
CompanyDeals

Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors

Bill & Melinda Gates Foundation Invests $17 Million in CanSino Biologics' Recombinant Polio Vaccine
CompanyDeals

Bill & Melinda Gates Foundation Invests $17 Million in CanSino Biologics’ Recombinant Polio Vaccine

InnoCare Pharma's ICP-488 Shows Promising Results in Phase II Psoriasis Study
CompanyDrug

InnoCare Pharma’s ICP-488 Shows Promising Results in Phase II Psoriasis Study

Ascletis Pharma Faces US Import Ban for NASH Drugs ASC41 and ASC43F in Trade Secrets Dispute
CompanyDrug

Ascletis Pharma Faces US Import Ban for NASH Drugs ASC41 and ASC43F in Trade Secrets Dispute

Beijing Aosaikang Pharmaceuticals Boosts Stake in US Subsidiary AskGene with RMB 220 Million Investment
CompanyDeals

Beijing Aosaikang Pharmaceuticals Boosts Stake in US Subsidiary AskGene with RMB 220 Million Investment

Eli Lilly China Appoints Yan Qiong as Vice President of Diabetes Business Unit
Company

Eli Lilly China Appoints Yan Qiong as Vice President of Diabetes Business Unit

Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services
Policy / Regulatory

Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services

InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment
CompanyDrug

InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment

Ascletis Pharma's ASC40 Earns FDA Breakthrough Therapy Designation for Fibrotic MASH
CompanyDrug

Ascletis Pharma’s ASC40 Earns FDA Breakthrough Therapy Designation for Fibrotic MASH

HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates
CompanyDeals

HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates

Sichuan Biokin's BL-B01D1 Earns Breakthrough Therapy Designation for Esophageal Cancer from China's CDE
CompanyDrug

Sichuan Biokin’s BL-B01D1 Earns Breakthrough Therapy Designation for Esophageal Cancer from China’s CDE

Merck's Keytruda Meets Primary Endpoint in Phase III Study for Head and Neck Cancer
CompanyDrug

Merck’s Keytruda Meets Primary Endpoint in Phase III Study for Head and Neck Cancer